Trial Profile
Open Label, Randomized, Multicentric Study To Establish Safety And Efficacy Of Recombinant Insulin Glargine Manufactured By Biocon Ltd Compared To LantusTM In Type 1 Diabetes Mellitus Patients.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Aug 2016
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Biocon
- 01 Jul 2009 New trial record